Washington: A study at the University of Copenhagen has shown that the previously efficacious drug chloroquine is once again beginning to work against malaria.
And scientists believe this will ensure cheaper treatment for the world’s poor.
Scientists and healthcare personnel the world over fear that the malarial parasite will develop resistance to the current frontline treatment against malaria, Artemisinin-based Combination Therapies (ACTs).
Therefore, it is especially good news that resistance monitoring at the University of Copenhagen shows that in several African countries, malaria parasites are succumbing to the formerly used drug chloroquine.
“70 percent of the malaria parasites we found in Senegal are reacting once again to chloroquine. This is a trend we have also seen in Tanzania and Mozambique, and which other researchers have shown in Malawi. Our choice of drugs against malaria is limited and related, so when the malaria parasite once again reacts to a substance, it influences several treatment methods,” explained Michael Alifrangis, associate professor at the Center for Medical Parasitology at the University of Copenhagen.
He and Magatte Ndiaye, PhD student at Universite Cheikh Anta Diop in Senegal, are keeping an eye on the malaria parasite’s sensitivity to drugs by analyzing the parasites’ DNA.
If healthcare personnel in developing countries can begin using chloroquine again, it will open up some promising perspectives. It will be possible to protect the currently used medicine and delay the reappearance of resistance, and it will also give a large group of patients access to cheaper treatment.
Chloroquine costs only 25 US cents for a four-day cure, while the current and corresponding ACTs cost two dollars, according to Professor Ib Bygbjerg M.D.
“Chloroquine was a fantastic malaria drug that lasted for 50 years. However, it was misused for malaria prevention and ordinary fever, and even mixed with cooking salt, so it can come as no surprise that the malaria parasite became resistant to the active ingredient,” explained Professor Bygbjerg.
He also pointed out that reuse will require correct drug use and the training of healthcare personnel to make more accurate diagnoses.
According to him, three factors determine the extent to which a malaria drug will work: 1) the size of the dose, 2) how sensitive the parasite is to the drug, and 3) the extent to which the patient has developed a natural immunity to malaria.
The results have just been published in the American Journal of Tropical Medicine and Hygiene.
ANI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.